ARCHIVES

Tivozanib Trumps Sorafenib In 1st-Line Renal Cancer Study

This article is from The Cancer Letter archive.

Vol. 35 No. 5 | May 25, 2012

Download PDF Visit The Full Archive

Related Articles

CDC: Lung Cancer Rates Drop Following Anti-Smoking Efforts

January 17, 2014

ODAC Member Critical Of Amgen For Price Incentives.

March 21, 2008

NCI Stops Trial Of Screening In Men To Add Women

November 2, 1990

An Angel In heaven – Or How Rejected Grants Do and Don’t Get Reviewed

May 3, 1974

Erbitux Plus Radiation, Chemo, Appears To Provide CRs In A Small Phase II Study

February 23, 2007

USLA’’s Steckel Asks More Centers Staff, Strict Enforcement of Guidelines

February 17, 1978